Photo by The Good Hygenie Co TGHC on Unsplash
- As of June 9, 2026, the FDA granted GRASE (Generally Recognized as Safe and Effective) status to bemotrizinol — the first new sunscreen active ingredient cleared for U.S. consumers since 1999, per the agency's official press release.
- DSM-Firmenich, which spent at least $18 million over more than two decades pursuing this approval, will sell it exclusively as Parsol Shield for 18 months beginning August 9, 2026, with retail products expected by September 2026.
- As of June 14, 2026, the U.S. recognizes 17 approved sunscreen active ingredients versus more than 30 in the European Union — a regulatory gap that left American consumers with fewer cosmetically elegant, residue-free options than their counterparts abroad.
- Melanoma cases are projected to reach 234,680 in 2026 — a 10.6% increase — while only 22% of men and 40% of women currently use SPF 15+ sunscreen daily, despite evidence that regular use reduces melanoma risk by roughly 50%.
The 25-Year Wait, Explained
25 years. That is the gap between the last FDA-approved sunscreen ingredient and June 9, 2026, the date the agency granted bemotrizinol GRASE status — clearing it for use in over-the-counter sunscreen products sold throughout the United States. The story behind that wait is partly science, partly regulatory architecture, and partly a cautionary tale about what happens when a federal approval framework outlives the innovation speed it was designed to evaluate.
According to reporting by KFF Health News and Medical Marketing and Media — which frames the approval primarily as an opportunity to rebuild consumer trust in a product category battered by ingredient-safety scares and inconsistent labeling — the decision lands at an inflection point for the entire sunscreen market. CBS News separately noted that DSM-Firmenich spent at least $18 million and more than two decades navigating the FDA process for this single compound. That expenditure is not incidental context. It explains why several other companies quietly abandoned similar applications years earlier: the economics of approval were simply prohibitive under the old rulemaking system.
Bemotrizinol has been commercially available in Europe, Australia, and parts of Asia since 1999. The compound delivers broad-spectrum protection against both UVA and UVB radiation, is photostable (meaning it does not degrade in sunlight the way some older chemical filters can), absorbs minimally through skin, and leaves no white residue — the cosmetic friction point that has historically driven consumers away from mineral-based alternatives like zinc oxide on deeper skin tones.
One timeline note worth flagging: most coverage describes this as the first new approval in 25 years, counting from 1999. The FDA's own press release uses the phrase "20 years." The discrepancy appears to stem from different reference points — the agency may be counting from its most recent prior sunscreen rulemaking cycle rather than a specific ingredient's commercial debut. Either framing underscores the same essential fact: this category has been static for a generation.
What the Evidence Actually Shows
The evidence tier here is unusually solid by consumer-product standards. Bemotrizinol did not arrive at the FDA as an experimental compound with only short-term pre-market trial data. It arrived with more than two decades of post-market safety experience across multiple continents — a meaningful distinction that the agency's GRASE framework is designed to recognize.
The Environmental Working Group (EWG), which filed a formal petition urging FDA action back in 2019, captured its position through Chief Science Officer Dr. David Andrews: "This is a great day for American consumers and everyone who has fought to improve sunscreen options and close the UVA protection gap in U.S. sunscreens." The EWG's multi-year advocacy role is part of what makes the Independent Institute's parallel critique worth reading: that outlet argued, as of June 12, 2026, that consumers are "still being burned by cronyism" because the 18-month exclusivity window rewards only the one company that could afford the regulatory marathon — not the broader market that would benefit from immediate competition.
Both perspectives are accurate simultaneously. The approval is genuinely good news. The exclusivity structure is a legitimate structural concern. Holding both is the evidence-first read here.
The clinical stakes are not abstract. Melanoma cases in the United States are projected to reach 234,680 in 2026 — a 10.6% rise, according to data cited across multiple health outlets. Regular use of SPF 15+ sunscreen has been shown to cut melanoma risk by approximately 50%. As of June 14, 2026, only 22% of men and 40% of women use that level of protection daily. The approval addresses the supply-side problem — giving manufacturers access to a more cosmetically acceptable formula. The demand-side behavior gap is a separate challenge that no regulatory decision resolves on its own.
Photo by Ian Hutchinson on Unsplash
The Sunscreen Coverage Gap — By the Numbers
Chart: As of June 14, 2026, the U.S. had 17 approved over-the-counter sunscreen active ingredients versus more than 30 in the European Union. Bemotrizinol's approval narrows — but does not close — that gap. Sources: FDA press release; Medical Marketing and Media.
That gap has carried real consequences for consumer behavior and product quality. Dermatologists have observed for years that patients returning from international travel noticed superior texture and protection in foreign-market formulations. Dr. Kavita Mariwalla, President of the American Society for Dermatologic Surgery, framed the approval's significance directly: "The addition of this sunscreen filter allows US manufacturers to formulate in a cosmetically elegant way, and the products will begin to achieve the look and feel of all the European and Japanese sunscreens that have gone viral." That phrase — "gone viral" — reflects what has been a slow-motion social media product comparison running for years, with U.S. consumers importing foreign sunscreens in meaningful numbers.
The CARES Act of 2020 replaced the old notice-and-comment rulemaking process (notoriously slow, requiring multi-year review cycles and full public comment periods) with a faster administrative order framework. Bemotrizinol is the first ingredient approved under that system. HHS Secretary Robert F. Kennedy Jr. called the action a step toward increased competition and consumer confidence — one of the clearer outcomes yet from the MAHA (Make America Healthy Again) initiative, which drew praise in this instance from advocacy groups across the political spectrum, including the EWG. In 2019, FDA had proposed requiring 16 existing sunscreen ingredients to undergo additional safety testing at an estimated industry cost of $3.5 billion, a proposal that caused several manufacturers to abandon their own filings. The new pathway makes that kind of chilling effect far less likely going forward.
What Shifts When Parsol Shield Hits Shelves
Practically speaking, change arrives in stages. DSM Nutritional Products begins exclusively supplying bemotrizinol under the Parsol Shield name to manufacturers on August 9, 2026. Consumer-facing sunscreen products are expected to reach retail shelves around September 2026, though individual brand timelines will vary by formulation speed. Health Canada had already approved Parsol Shield for Canadian sunscreens before the U.S. ruling, meaning some cross-border shoppers may have already encountered it.
For those tracking personal finance decisions around health products, the near-term picture is reasonably predictable: premium brands will be the earliest adopters, positioning bemotrizinol as a differentiating feature during the 18-month exclusivity window. Expect a price premium on those early-market products. Once the exclusivity period ends (approximately February 2028), broader manufacturer access should push pricing toward current market norms. Investors watching the personal care sector in their investment portfolio may find the DSM exclusivity period worth monitoring — it creates a short window of pricing power before generic competition resumes.
The regulatory modernization that made this approval possible also reflects a broader infrastructure shift. The move from open-ended rulemaking to administrative orders mirrors trends in pharmaceutical development, where data aggregation tools — including machine learning pipelines used to synthesize large international safety datasets — are compressing what used to be decade-long review timelines. The bemotrizinol approval was not driven by AI, but the administrative order framework it traveled through was built on the same logic: use accumulated data more efficiently, reduce redundant process steps, and make evidence-based decisions faster. That philosophy is reshaping how healthcare innovation moves from laboratory to consumer across multiple categories simultaneously.
If you currently rely on a vitamin d supplement partly because aggressive sun avoidance has become your default strategy, the availability of a more cosmetically acceptable, high-performance sunscreen option is worth discussing with your dermatologist — better protection tools can change the calculus on managed outdoor exposure.
Frequently Asked Questions
What is bemotrizinol and how does it differ from zinc oxide or avobenzone in sunscreen?
Bemotrizinol is a chemical sunscreen filter that absorbs and neutralizes both UVA and UVB radiation, much like avobenzone — but with a key advantage: it is photostable, meaning it does not break down in sunlight. Avobenzone degrades with UV exposure unless paired with photostabilizers, while zinc oxide (a mineral filter) is inherently stable but can leave a visible white cast. Bemotrizinol is photostable, residue-free, and has minimal skin absorption, making it a meaningful upgrade over both in cosmetic acceptability for many users.
When will bemotrizinol sunscreen be available in stores in the U.S.?
As of June 14, 2026, DSM Nutritional Products is scheduled to begin selling bemotrizinol as Parsol Shield to manufacturers on August 9, 2026 — the effective date of the FDA's administrative order. Consumer-facing products are expected to appear on retail shelves around September 2026. During the initial 18-month exclusivity period, only products formulated with DSM-licensed ingredient will carry bemotrizinol; broader market availability is expected after approximately February 2028.
Is bemotrizinol safe for daily use, and how strong is the evidence behind the FDA's approval?
The ingredient has been in commercial use in Europe, Australia, and parts of Asia since 1999 — providing more than two decades of post-market safety data that informed the FDA's GRASE designation. This is a stronger evidence base than many consumer product approvals, which rely primarily on pre-market trials with shorter follow-up windows. The systematic review of available data led the FDA to conclude it meets the threshold for general recognition as safe and effective. Individual sensitivities to topical ingredients always vary, so consulting a dermatologist remains reasonable — particularly for people with sensitive skin or known reactions to chemical sunscreen filters.
Why did it take over 20 years for FDA to approve bemotrizinol when Europe had it since 1999?
The core issue was regulatory structure, not safety science. Under the pre-CARES Act framework, new sunscreen ingredients required full FDA rulemaking — a process involving public comment periods, U.S.-standard safety studies, and review timelines measured in years. A 2019 FDA proposal to require additional safety testing for 16 existing ingredients, at an estimated industry cost of $3.5 billion, caused several manufacturers to walk away from pending applications entirely. DSM-Firmenich persisted, spending at least $18 million over more than two decades, and became the first company to clear the new, faster administrative order pathway created by the CARES Act of 2020. The first-filing date for bemotrizinol with the FDA was 2005 — meaning the formal U.S. review process alone took 21 years.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, medical, or investment advice. Readers should consult a qualified healthcare provider before making changes to sun protection or supplement routines, and a licensed financial advisor before making investment decisions. Research based on publicly available sources current as of June 14, 2026.